BLFS

BioLife Solutions, Inc. is a leading developer, manufacturer, and supplier of proprietary clinical-grade bioproduction tools and services for the cell and gene therapy industry. Headquartered in Bothell, Washington, BioLife provides enabling technologies that improve the effectiveness of clinical trials and commercial cell and gene therapy manufacturing. The company's products and services span the cell therapy production workflow from initial collection and processing through preservation, storage, cryopreservation, and thawing, addressing critical needs in maintaining cell viability, function, and genetic stability throughout manufacturing processes. BioLife's core products include biopreservation media (CryoStor for cryopreservation and HypoThermosol for hypothermic storage), ThawSTAR automated thawing systems that rapidly and uniformly thaw frozen cell therapy products, evo shipping containers providing controlled-rate freezing and stable temperature maintenance during transport, and laboratory Cold Chain Management services including storage, distribution, and logistics for biologic materials. These products are scientifically formulated and rigorously tested to preserve cell health and function, critical for ensuring therapeutic efficacy and patient safety in cell and gene therapies. The company serves pharmaceutical and biotechnology companies, academic research institutions, and cell and gene therapy manufacturers developing treatments for cancer, autoimmune disorders, infectious diseases, and other conditions. BioLife's solutions are used in production of CAR-T therapies, stem cell treatments, regenerative medicine products, and other advanced therapeutics. The company operates in a rapidly growing market driven by explosive expansion of cell and gene therapy development with hundreds of programs in clinical trials and increasing commercial approvals. BioLife has established critical infrastructure position in the cell therapy supply chain. Growth strategy includes organic innovation, strategic acquisitions expanding product portfolio, international expansion, and capturing increasing share of growing cell and gene therapy market. BioLife generates revenue from product sales, services, and recurring cold chain management contracts.